Trial Information

Summary: Randomized Phase II Study of Thalidomide Versus Thalidomide Plus Fludarabine for Patients with Chronic Lymphocytic Leukemia Previously Treated with Fludarabine

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already received fludarabine are randomized to receive either fludarabine plus thalidomide or thalidomide alone
No Compensation Provided

Patient Inclusion/Exclusion Criteria:

1. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
2. Previously treated with fludarabine


1. Other concurrent malignancies.
2. Concurrent anti-cancer therapy
3. History of abnormal heart rhythm or heart attack.

Contact:

Richard Furman, M.D.
Mount Sinai Medical Center
One Gustave L. Levy Place

New York, NY 10029
Telephone: 212 241-5454
Fax: 212 876-5276
Email:

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:43:32 AM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA